secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-05-13T20:02:03+00:00
Accession:  0001193125-26-221567
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero posts Q1 net loss of $7.2M; tebipenem HBr PDUFA date June 18, 2026
------------------------------------------------------------------------

- Net loss of $7.2M ($0.13 diluted EPS) vs $13.9M loss ($0.25 EPS) in Q1 2025.
- Total revenue of $0.3M, down from $5.9M in prior-year quarter.
- Cash and equivalents of $56.1M as of March 31, 2026; cash runway into 2028.
- GSK-led NDA for tebipenem HBr in cUTI under FDA review with PDUFA date June 18, 2026.
- R&D expenses fell to $2.9M from $13.6M due to Phase 3 trial completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/0001193125-26-221567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer